Interleukin-6 blockade abrogates immunotherapy toxicity and promotes tumor immunityYared Hailemichael, Adi Diab, Daniel H. Johnson et al.|Cancer Cell|2022Cited by 338
Anti-PD1 checkpoint inhibitor therapy in acral melanoma: a multicenter study of 193 Japanese patientsYasuhiro Nakamura, N. Yamazaki, Haruki Doi et al.|Annals of Oncology|2020Cited by 140
Clinical characteristics associated with BRAF, NRAS and KIT mutations in Japanese melanoma patientsKaori Sakaizawa, Hisashi Uhara, Atsuko Ashida et al.|Journal of Dermatological Science|2015Cited by 120
Clinical and histopathological characteristics and survival analysis of 4594 Japanese patients with melanomaYasuhiro Fujisawa, Norito Katoh, Shusuke Yoshikawa et al.|Cancer Medicine|2019Cited by 111
Anti-PD-1 antibody monotherapy versus anti-PD-1 plus anti-CTLA-4 combination therapy as first-line immunotherapy in unresectable or metastatic mucosal melanoma: a retrospective, multicenter study of 329 Japanese cases (JMAC study)Yasuhiro Nakamura, Naoya Yamazaki, Kenjiro Namikawa et al.|ESMO Open|2021Cited by 57